All In Biotech

Drug Trial Radar · NCT05587322

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 788 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

788

Actual

Start

Sep 6, 2022

Primary completion

Oct 13, 2023

Study completion Apr 23, 2024

Sponsor

Lead sponsor
Braintree LaboratoriesIndustry
Sponsor type
Industry
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD. The objective of the Extension Phase of the study is to evaluate the safety of extended exposure to once daily oral administration of BLI5100 low dose and BLI5100 high dose in patients with NERD.

Conditions

  • Non-erosive Reflux Disease

Interventions

  • BLI5100Drug

    Orally via tablet

  • PlaceboDrug

    Orally via tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of 24-Hour Heartburn Free Days Through Week 4 of Treatment PhaseTime frame: 4 Weeks

Locations

112 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 24

    Huntsville, Alabama

  • Research Site 132

    Peoria, Arizona

  • Research Site 62

    Phoenix, Arizona

  • Research Site 27

    Tucson, Arizona

  • Research Site 87

    Little Rock, Arkansas

  • Research Site 117

    North Little Rock, Arkansas

  • Research Site 51

    Arcadia, California

  • Research Site 126

    Bakersfield, California

  • Research Site 66

    Bell Gardens, California

  • Research Site 19

    Canoga Park, California

  • Research Site 94

    Chula Vista, California

  • Research Site 10

    Huntington Park, California

  • Research Site 55

    La Mesa, California

  • Research Site 120

    Long Beach, California

  • Research Site 72

    Los Angeles, California

  • Research Site 54

    Los Angeles, California

  • Research Site 18

    Mission Viejo, California

  • Research Site 14

    San Diego, California

  • Research Site 85

    Santa Ana, California

  • Research Site 13

    Santa Ana, California

  • Research Site 41

    Santa Maria, California

  • Research Site 112

    Aurora, Colorado

  • Research Site 89

    Littleton, Colorado

  • Research Site 74

    Boca Raton, Florida

  • Research Site 108

    Cooper City, Florida

  • Research Site 91

    Doral, Florida

  • Research Site 03

    Hialeah, Florida

  • Research Site 78

    Homestead, Florida

  • Research Site 09

    Lake City, Florida

  • Research Site 23

    Maitland, Florida

  • Research Site 38

    Miami, Florida

  • Research Site 43

    Miami, Florida

  • Research Site 81

    Miami, Florida

  • Research Site 67

    Miami, Florida

  • Research Site 92

    Miami, Florida

  • Research Site 31

    Miami, Florida

  • Research Site 71

    Miami, Florida

  • Research Site 42

    Miami Lakes, Florida

  • Research Site 17

    New Port Richey, Florida

  • Research Site 90

    Ocoee, Florida

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.